Background: A novel series of 2-(Morpholin-4-yl)-N-phenylquinazolin-4-
amine derivatives were synthesized and confirmed with spectral and elemental techniques.
Methods: The compounds were tested for analgesic and anti-inflammatory activity by various
pain models in rodents whereas the selectivity towards COX-2 receptor is determined
by in vitro assay.
Results: Screening results of compounds exhibited comparable biological activity with that
of standard compound Indomethacin used for study. Compound 5d was found to be significantly
potent with respect to its anti-inflammatory and analgesic activity with substantial
Conclusion: In silico analysis by molecular docking and 3D-QSAR studies justifies activity
profile of compound 5d, suggesting that it may have potential for further evaluation and
development as lead molecule for therapy in pain management.